San Francisco, United States
Delinia is a biotechnology company at the forefront of developing innovative treatments for autoimmune and inflammatory diseases. Founded in 2015 and headquartered in the United States, the company focuses on enhancing Regulatory T Cells (Tregs) to maintain immune system balance. These powerful immune cells are essential for self-tolerance and play a significant role in the pathophysiology of cancer and autoimmune diseases.
The company recently gained attention with a substantial $35.00M Series A investment on 14 September 2016, with notable support from Atlas Venture and Sofinnova Partners. Delinia's lead program aims to potentiate and expand Tregs, positioning itself firmly within the Biotechnology and Health and Wellness sectors. With its commitment to pioneering breakthrough treatments, Delinia stands out as a promising player in the quest to combat autoimmune diseases.
